autologous cord blood cells

Autologous cord blood cells are **blood stem and progenitor cells collected from a newborn's own umbilical cord blood at birth and then stored for potential future therapeutic use**. Unlike allogeneic cord blood transplants (from a donor), autologous therapy uses cells derived from the same individual, eliminating the risk of immune rejection. The stem and progenitor cells in autologous cord blood can regenerate hematopoietic (blood-forming) and immune systems and also possess potential for tissue repair and immune modulation. Current research and clinical trials have explored their use in treating conditions such as **type 1 diabetes, hypoplastic left heart syndrome, autism spectrum disorder, cerebral palsy, and complications of prematurity**, as well as their established role in **hematopoietic reconstitution following myeloablative therapy**. Mechanisms of action include hematopoietic reconstitution, support for endogenous tissue repair, immune modulation via regulatory T cells, paracrine signaling, and potential differentiation into various specialized cell types[2][3][5][7][9].

Other names

autologous umbilical cord blood cellsautologous cord bloodautologous umbilical cord bloodACBautologous cord blood mononuclear cells